IMHODMA\iManage;143454;1

nahu-1645 Box SEQ

PATENT APPLICATION Docket No.: 0050.1618-000 (Formerly MIT-8503)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Leonard Guarente, Shin-ichiro Imai and Christopher Armstrong

RECEIVED

JUL 21 5000

TECH CENTER 1600/2900

Applicants:

Group Art Unit:

1645

Serial No.:

09/461,580

Filed:

December 15, 1999

Examiner:

R. Zeman

For:

METHODS FOR IDENTIFYING AGENTS WHICH ALTER

HISTONE PROTEIN ACETYLATION, DECREASE AGING,

INCREASE LIFESPAN

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents.

Washington, D.£

Typed or printed name of person signing certificate

TRANSMITTAL OF SEQUENCE LISTING AND PRELIMINARY AMENDMENT IN RESPONSE TO NOTICE TO COMPLY WITH 37 C.F.R. §§1.821-1.825

Box Sequence

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

This amendment is submitted in response to an Office Communication from the Examiner and the Notice to Comply with Sequence Rules 37 C.F.R. §§1.821-1.825 attached thereto, mailed from the Patent Office on June 12, 2000, copies of which are attached.

Transmitted herewith is a copy of the "Sequence Listing" (sheets 1/24 through

JUI 21 2235

TECH CENTER 1600/2500

24/24) in paper form for the above-identified patent application as required by 37 C.F.R. §1.821(c) and a copy of the "Sequence Listing" in computer readable form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicants' Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Applicants' Attorney submits the following amendment to comply with 37 C.F.R. §1.825:

In the Specification

Please insert the attached "Sequence Listing" (sheets 1/24 through 24/24), and comprising SEQ ID NOS: 1-35, into the above-referenced application.

CONCLUSION

If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (781) 861-6240.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

N. Scott Pierce

Registration No. 34,900

Telephone (781) 861-6240

Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799





DEA/FCE-1994

SERIAL NUMBER FILING DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NO. 09 1461580

EXA	AMINER
ART UNIT	PAPER NUMBER
	5
DATE MAILED:	

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

- This application contains sequence disclosures that are encompassed by 1. the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.
- 2. Any inquiry concerning this communication should be directed to Examiner Robert A. Zeman, Art Unit 1645, whose telephone number is (703)308-7991.
- 3. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.
- 4. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice to Comply.
- 5. APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

June 6, 2000 Robert A. Zeman

PRIMARY EXAMINER

CC

Application No.:09/461580 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)



- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

	•	, , , , , , , , , , , , , , , , , , , ,
X	3. A copy of 37 C.F.R	f the "Sequence Listing" in computer readable form has not been submitted as required by . 1.821(e).
	content o	the "Sequence Listing" in computer readable form has been submitted. However, the f the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
ļ	and/or un	outer readable form that has been filed with this application has been found to be damaged readable as indicated on the attached CRF Diskette Problem Report. A Substitute readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper "Sequence	copy of the "Sequence Listing" is not the same as the computer readable from of the Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:	
Ap X		st Provide: substitute computer readable form (CRF) copy of the "Sequence Listing".

An <u>initial or_substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE